These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 9364678)

  • 1. The muramyl dipeptide analog GMTP-N-DPG preferentially induces cellular immunity to soluble antigens.
    Fast DJ; Vosika GJ
    Vaccine; 1997 Nov; 15(16):1748-52. PubMed ID: 9364678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of a CD8+ cytotoxic T lymphocyte response to soluble antigen given together with a novel muramyl dipeptide adjuvant, N-acetyl-D-glucosaminyl-(beta 1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP).
    Hornung RL; Longo DL; Gowda VL; Kwak LW
    Ther Immunol; 1995 Feb; 2(1):7-14. PubMed ID: 7553072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses.
    Newman MJ; Wu JY; Gardner BH; Munroe KJ; Leombruno D; Recchia J; Kensil CR; Coughlin RT
    J Immunol; 1992 Apr; 148(8):2357-62. PubMed ID: 1373166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological adjuvant effect of Boswellia serrata (BOS 2000) on specific antibody and cellular response to ovalbumin in mice.
    Gupta A; Khajuria A; Singh J; Singh S; Suri KA; Qazi GN
    Int Immunopharmacol; 2011 Aug; 11(8):968-75. PubMed ID: 21371582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B30-MDP, a synthetic muramyl dipeptide derivative for tumour vaccination to enhance antitumour immunity and antimetastatic effect in mice.
    Yoo YC; Saiki I; Sato K; Azuma I
    Vaccine; 1992; 10(11):792-7. PubMed ID: 1441733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant activity of muramyl dipeptide derivatives to enhance immunogenicity of a hantavirus-inactivated vaccine.
    Yoo YC; Yoshimatsu K; Koike Y; Hatsuse R; Yamanishi K; Tanishita O; Arikawa J; Azuma I
    Vaccine; 1998; 16(2-3):216-24. PubMed ID: 9607033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel immunostimulator, N-[alpha-O-benzyl-N-(acetylmuramyl)-L-alanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-L-lysine, and its adjuvancy on the hepatitis B surface antigen.
    Yang HZ; Xu S; Liao XY; Zhang SD; Liang ZL; Liu BH; Bai JY; Jiang C; Ding J; Cheng GF; Liu G
    J Med Chem; 2005 Aug; 48(16):5112-22. PubMed ID: 16078831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Enhancement of the activity of hepatitis B virus vaccine by association with murabutide].
    Audibert F; Przewlocki G; Lefrancier P; Choay J; Chedid L
    C R Seances Acad Sci III; 1982 Nov; 295(10):611-4. PubMed ID: 6218866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of immunomodulatory properties of N-acetylmuramyl-L-alanyl-D-isoglutamine and N-acetylglucosaminyl-(beta 1----4)-N-acetylmuramyl-L-alanyl-D-isoglutamine.
    Dozmorov IM; Kuzin II; Lutsan NI; Lutsenko GV; Prokhorova AL; Sapozhnikov AM; Andronova TM; Ivanov VT
    Biomed Sci; 1991; 2(6):651-8. PubMed ID: 1841635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
    Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Well-defined and potent liposomal hepatitis B vaccines adjuvanted with lipophilic MDP derivatives.
    Jain V; Vyas SP; Kohli DV
    Nanomedicine; 2009 Sep; 5(3):334-44. PubMed ID: 19523433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monophosphoryl lipid A enhances specific CTL induction by a soluble protein antigen entrapped in liposomes.
    Zhou F; Huang L
    Vaccine; 1993; 11(11):1139-44. PubMed ID: 8249434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of Antigen Adjuvanted with AS04 and Its Deposition in the Upper Respiratory Tract after Intranasal Administration.
    Xu H; Alzhrani RF; Warnken ZN; Thakkar SG; Zeng M; Smyth HDC; Williams RO; Cui Z
    Mol Pharm; 2020 Sep; 17(9):3259-3269. PubMed ID: 32787271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramyl peptides and bacterial lipopolysaccharides with bovine serum albumin.
    Ogawa T; Kotani S; Shimauchi H
    Methods Find Exp Clin Pharmacol; 1986 Feb; 8(2):117-25. PubMed ID: 3713372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement by murabutide of the immune response to natural and synthetic hepatitis B surface antigens.
    Audibert FM; Przewlocki G; Leclerc CD; Jolivet ME; Gras-Masse HS; Tartar AL; Chedid LA
    Infect Immun; 1984 Jul; 45(1):261-6. PubMed ID: 6735468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of muramyl dipeptide derivatives as adjuvants on the induction of antibody response to recombinant hepatitis B surface antigen.
    Tamura M; Yoo YC; Yoshimatsu K; Yoshida R; Oka T; Ohkuma K; Arikawa J; Azuma I
    Vaccine; 1995 Jan; 13(1):77-82. PubMed ID: 7762283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine.
    Koike Y; Yoo YC; Mitobe M; Oka T; Okuma K; Tono-oka S; Azuma I
    Vaccine; 1998 Dec; 16(20):1982-9. PubMed ID: 9796054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Muramyl dipeptide and its synthetic analog as possible inducers of interleukin-2 production].
    Malaĭtsev VV; Bogdanov IM; Sukhikh GT; Andronova TM
    Biull Eksp Biol Med; 1985 Aug; 100(8):221-3. PubMed ID: 3875372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant activity of peptidoglycan monomer and its metabolic products.
    Halassy B; Krstanović M; Frkanec R; Tomasić J
    Vaccine; 2003 Feb; 21(9-10):971-6. PubMed ID: 12547610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Immunological Functions of Muramyl Dipeptide Compound Adjuvant on Humoral, Cellular-mediated and Mucosal Immune Responses to PEDV Inactivated Vaccine in Mice.
    Zhou CJ; Chen J; Hou JB; Zheng Y; Yu YN; He H; Zhang YP; Feng XL; Zheng QS
    Protein Pept Lett; 2018; 25(10):908-913. PubMed ID: 30227812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.